PB 33 of 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 23 April 2024   

Nikolai Tsyganov

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1  Name...................................................1

2  Commencement............................................1

3  Authority................................................1

4  Schedules................................................1

Schedule 1—Amendments—Additional designated brands effective from 1 August 2024              2

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023              2

Schedule 2—Amendments—Additional designated brands effective from 1 October 2024              3

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023              3

1  Name

 (1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2024.

 (2) This instrument may also be cited as PB 33 of 2024.

2  Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

  This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4  Schedules

  Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments—Additional designated brands effective from 1 August 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (after table item dealing with the brand Penthrox of the drug Methoxyflurane in the form Liquid for inhalation 999 mg per g, 3 ml (with inhaler))

Insert:

Schedule 2—Amendments—Additional designated brands effective from 1 October 2024

National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1  Section 5 (before table item dealing with the brand PKU squeezie of the drug Amino acid formula with vitamins and minerals without phenylalanine in the form Oral gel 85 g, 30 (PKU squeezie)

Insert:

2  Section 5 (after table item dealing with the brand Bicillin L-A of the drug Benzathine benzylpenicillin in the form Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe)

Insert:

3  Section 5 (after table item dealing with the brand Triumeq of the drug Dolutegravir with abacavir and lamivudine in the form Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg)

Insert:

4  Section 5 (after table item dealing with the brand Flucil of the drug Flucloxacillin in the form Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL)

Insert:

5  Section 5 (after table item dealing with the brand Toujeo Solostar of the drug Insulin glargine in the form Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5)

Insert:

6  Section 5 (after table item dealing with the brand OsmoLax of the drug Macrogol 3350 in the form Powder for oral solution 510 g)

Insert:

7  Section 5 (after table item dealing with the brand Penthrox of the drug Methoxyflurane in the form Liquid for inhalation 999 mg per g, 3 ml (with inhaler))

Insert:

8  Section 5 (after table item dealing with the brand Stemetil of the drug Prochlorperazine in the form Injection containing prochlorperazine mesilate 12.5 mg in 1 mL)

Insert:

9  Section 5 (after table item dealing with the brand Aptamil Gold+ Pepti-Junior of the drug Protein hydrolysate formula with medium chain triglycerides in the form Oral powder 450 g (Aptamil Gold+ Pepti-Junior))

Insert:

10  Section 5 (after table item dealing with the brand Micolette of the drug Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate in the form Enemas 3.125 g-450 mg-45 mg in 5 mL, 12)

Insert: